L. Boumsell, A. Bernard, V. Lepage, L. Degos, J. Lemerle et al., Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells, European Journal of Immunology, vol.39, issue.12, pp.900-904, 1978.
DOI : 10.1002/eji.1830081214

R. Damle, F. Ghiotto, A. Valetto, E. Albesiano, F. Fais et al., B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes, Blood, vol.99, issue.11, pp.4087-4093, 2002.
DOI : 10.1182/blood.V99.11.4087

G. Friedlein, E. Hage, F. Vergnon, I. Richon, C. Saulnier et al., Human CD5 Protects Circulating Tumor Antigen-Specific CTL from Tumor-Mediated Activation-Induced Cell Death, The Journal of Immunology, vol.178, issue.11, pp.6821-6827, 2007.
DOI : 10.4049/jimmunol.178.11.6821

H. Gary-gouy, J. Harriague, G. Bismuth, C. Platzer, C. Schmitt et al., Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production, Blood, vol.100, issue.13, pp.4537-4543, 2002.
DOI : 10.1182/blood-2002-05-1525

R. Dillman, D. Shawler, J. Dillman, and I. Royston, Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody., Journal of Clinical Oncology, vol.2, issue.8, pp.881-891, 1984.
DOI : 10.1200/JCO.1984.2.8.881

R. Miller, A. Oseroff, P. Stratte, and R. Levy, Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma, Blood, vol.62, pp.988-995, 1983.

A. Hertler, D. Schlossman, M. Borowitz, G. Laurent, F. Jansen et al., A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia, J Biol Response Mod, vol.7, pp.97-113, 1988.

F. Foss, A. Raubitscheck, J. Mulshine, T. Fleisher, J. Reynolds et al., Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma, Clin Cancer Res, vol.4, pp.2691-2700, 1998.

D. Cioca and K. Kitano, Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia, Leukemia, vol.16, issue.3, pp.335-343, 2002.
DOI : 10.1038/sj.leu.2402393

. Loisel, Molecular Cancer http://www.molecular-cancer.com/content, p.4242, 2011.

J. Pers, C. Berthou, N. Porakishvili, M. Burdjanadze, L. Calvez et al., CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia, Leukemia, vol.16, issue.1, pp.44-52, 2002.
DOI : 10.1038/sj.leu.2402327

T. Daniels, T. Delgado, J. Rodriguez, G. Helguera, and M. Penichet, The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer, Clinical Immunology, vol.121, issue.2, pp.144-158, 2006.
DOI : 10.1016/j.clim.2006.06.010

K. Gatter, G. Brown, I. Trowbridge, R. Woolston, and D. Mason, Transferrin receptors in human tissues: their distribution and possible clinical relevance., Journal of Clinical Pathology, vol.36, issue.5, pp.539-545, 1983.
DOI : 10.1136/jcp.36.5.539

D. Gupta, A. Shah, and V. , Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin's lymphoma, Hematol Pathol, vol.4, pp.37-41, 1990.

R. Taetle, J. Honeysett, and I. Trowbridge, Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells, International Journal of Cancer, vol.78, issue.3, pp.343-349, 1983.
DOI : 10.1002/ijc.2910320314

D. Brooks, C. Taylor, D. Santos, B. Linden, H. Houghton et al., Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42, Clin Cancer Res, vol.1, issue.6, pp.1259-1265, 1995.

Y. Qing, W. Shuo, W. Zhihua, Z. Huifen, L. Ping et al., The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor, Cancer Immunology, Immunotherapy, vol.104, issue.6, pp.1111-1121, 2006.
DOI : 10.1007/s00262-005-0105-7

J. Kaufman, C. Auffray, A. Korman, D. Shackelford, and J. Strominger, The class II molecules of the human and murine major histocompatibility complex, Cell, vol.36, issue.1, pp.1-13, 1984.
DOI : 10.1016/0092-8674(84)90068-0

M. Newell, J. Vanderwall, K. Beard, and J. Freed, Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes., Proceedings of the National Academy of Sciences, vol.90, issue.22, pp.10459-10463, 1993.
DOI : 10.1073/pnas.90.22.10459

T. Yoshino, L. Cao, R. Nishiuchi, Y. Matsuo, I. Yamadori et al., Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis, European Journal of Immunology, vol.24, issue.8, pp.2190-2194, 1995.
DOI : 10.1002/eji.1830250811

J. Golay, L. Bologna, P. André, F. Buchegger, J. Mach et al., Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death, Blood, vol.116, issue.17, pp.3372-3375, 2010.
DOI : 10.1182/blood-2010-06-289736

G. Denardo, K. Lamborn, D. Goldstein, L. Kroger, and S. Denardo, Increased survival associated with radiolabeled lym-1 therapy for non-hodgkin's lymphoma and chronic lymphocytic leukemia, Cancer, vol.55, issue.S12, pp.2706-2711, 1997.
DOI : 10.1002/(SICI)1097-0142(19971215)80:12+<2706::AID-CNCR49>3.0.CO;2-D

K. Brown, D. Levitt, M. Shannon, and B. Link, Phase II Trial of Remitogen??? (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma, Clinical Lymphoma, vol.2, issue.3, pp.188-190, 2001.
DOI : 10.3816/CLM.2001.n.026

K. Dunleavy, T. White, N. Grant, M. Shovlin, M. Stetler-stevenson et al., Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia, Journal of Clinical Oncology, vol.23, issue.16_suppl, p.6607, 2005.
DOI : 10.1200/jco.2005.23.16_suppl.6607

G. Kansas and T. Tedder, Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinasedependent pathway, J Immunol, vol.147, pp.4094-4102, 1991.

W. Mourad, R. Geha, and T. Chatila, Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion, Journal of Experimental Medicine, vol.172, issue.5, pp.1513-1516, 1990.
DOI : 10.1084/jem.172.5.1513

J. Uchida, Y. Hamaguchi, J. Oliver, J. Ravetch, J. Poe et al., The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor???dependent Mechanisms during Anti-CD20 Antibody Immunotherapy, The Journal of Experimental Medicine, vol.16, issue.12, pp.1659-1669, 2004.
DOI : 10.1016/S0022-1759(00)00346-X

M. Leidi, E. Gotti, L. Bologna, E. Miranda, M. Rimoldi et al., M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro, The Journal of Immunology, vol.182, issue.7, pp.4415-4422, 2009.
DOI : 10.4049/jimmunol.0713732

M. Introna and J. Golay, Complement in antibody therapy: friend or foe?, Blood, vol.114, issue.26, pp.5247-5248, 2009.
DOI : 10.1182/blood-2009-10-249532

R. Clynes, T. Towers, L. Presta, and J. Ravetch, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, vol.6, pp.443-446, 2000.

G. Cartron, L. Dacheux, G. Salles, P. Solal-celigny, P. Bardos et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene, Blood, vol.99, issue.3, pp.754-758, 2002.
DOI : 10.1182/blood.V99.3.754

A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti et al., ???Positive Metastatic Breast Cancer, Journal of Clinical Oncology, vol.26, issue.11, pp.1789-1796, 2008.
DOI : 10.1200/JCO.2007.14.8957

C. Larbouret, B. Robert, C. Bascoul-mollevi, F. Penault-llorca, A. Ho-pun-cheung et al., Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts, Annals of Oncology, vol.21, issue.1, pp.98-103
DOI : 10.1093/annonc/mdp496
URL : https://hal.archives-ouvertes.fr/inserm-00431431

S. Bondada, G. Bikah, D. Robertson, and G. Sen, Role of CD5 in growth regulation of B-1 cells, Curr Top Microbiol Immunol, vol.252, pp.141-149, 2000.
DOI : 10.1007/978-3-642-57284-5_15

J. Folkman and . Angiogenesis, Angiogenesis, Annual Review of Medicine, vol.57, issue.1, pp.1-18, 2006.
DOI : 10.1146/annurev.med.57.121304.131306

M. Dechant, J. Bruenke, and T. Valerius, HLA class II antibodies in the treatment of hematologic malignancies, Seminars in Oncology, vol.30, issue.4, pp.465-475, 2003.
DOI : 10.1016/S0093-7754(03)00252-5

J. Leonard, S. Schuster, C. Emmanouilides, F. Couture, N. Teoh et al., Durable complete responses from therapy with combined epratuzumab and rituximab, Cancer, vol.107, issue.11, pp.2714-2723, 2008.
DOI : 10.1002/cncr.23890

S. Faderl, D. Thomas, O. Brien, S. Garcia-manero, G. Kantarjian et al., Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies, Blood, vol.101, issue.9, pp.3413-3415, 2003.
DOI : 10.1182/blood-2002-07-1952

C. Nabhan, D. Patton, L. Gordon, M. Riley, T. Kuzel et al., A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL), Leukemia & Lymphoma, vol.29, issue.2, pp.2269-2273, 2004.
DOI : 10.1182/blood-2002-01-0159

J. Tonra, D. Deevi, E. Corcoran, H. Li, S. Wang et al., Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy, Clinical Cancer Research, vol.12, issue.7, pp.2197-2207, 2006.
DOI : 10.1158/1078-0432.CCR-05-1682

C. Larbouret, B. Robert, I. Navarro-teulon, S. Thezenas, M. Ladjemi et al., In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas, Clinical Cancer Research, vol.13, issue.11, pp.3356-3362, 2007.
DOI : 10.1158/1078-0432.CCR-06-2302
URL : https://hal.archives-ouvertes.fr/inserm-00153693

S. Loisel, K. Ster, I. Quintin-roue, J. Pers, A. Bordron et al., Establishment of a novel human B-CLL-like xenograft model in nude mouse, Leukemia Research, vol.29, issue.11, pp.1347-1352, 2005.
DOI : 10.1016/j.leukres.2005.04.017

A. Rickers, N. Peters, V. Badock, R. Beyaert, P. Vandenabeele et al., Cleavage of transcription factor SP1 by caspases during anti-IgM-induced B-cell apoptosis, European Journal of Biochemistry, vol.72, issue.1, pp.269-274, 1999.
DOI : 10.1016/0092-8674(90)90296-Q

A. Schaffland, F. Buchegger, M. Kosinski, C. Antonescu, C. Paschoud et al., 131I-rituximab: relationship between immunoreactivity and specific activity, J Nucl Med, vol.45, pp.1784-1790, 2004.

T. Lindmo, E. Boven, F. Cuttitta, J. Fedorko, P. Bunn et al., Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess, Journal of Immunological Methods, vol.72, issue.1, pp.77-89, 1984.
DOI : 10.1016/0022-1759(84)90435-6

J. Golay, E. Cittera, D. Gaetano, N. Manganini, M. Mosca et al., The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes, Haematologica, vol.91, pp.176-183, 2006.

. Loisel, Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia, Molecular Cancer, vol.10, issue.1, p.42, 2011.
DOI : 10.1016/0022-1759(84)90435-6
URL : https://hal.archives-ouvertes.fr/inserm-00596532

. Loisel, Molecular Cancer http://www.molecular-cancer.com/content, p.4242, 2011.